Frazier Life Sciences Management’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.1M | Hold |
10,259,409
| – | – | 2.24% | 11 |
|
|
2025
Q1 | $64.5M | Sell |
10,259,409
-405,365
| -4% | -$2.55M | 2.95% | 9 |
|
|
2024
Q4 | $43.9M | Buy |
10,664,774
+3,283,684
| +44% | +$13.5M | 1.82% | 14 |
|
|
2024
Q3 | $24.7M | Hold |
7,381,090
| – | – | 0.99% | 25 |
|
|
2024
Q2 | $22M | Hold |
7,381,090
| – | – | 1.03% | 26 |
|
|
2024
Q1 | $25.5M | Hold |
7,381,090
| – | – | 1.07% | 27 |
|
|
2023
Q4 | $9.89M | Buy |
7,381,090
+500,000
| +7% | +$670K | 0.53% | 42 |
|
|
2023
Q3 | $15M | Hold |
6,881,090
| – | – | 1% | 24 |
|
|
2023
Q2 | $16.4M | Buy |
6,881,090
+217,500
| +3% | +$520K | 0.98% | 28 |
|
|
2023
Q1 | $12.3M | Hold |
6,663,590
| – | – | 0.89% | 26 |
|
|
2022
Q4 | $12.9M | Buy |
6,663,590
+1,260,000
| +23% | +$2.43M | 0.8% | 25 |
|
|
2022
Q3 | $8.32M | Buy |
5,403,590
+4,231,963
| +361% | +$6.52M | 0.64% | 33 |
|
|
2022
Q2 | $3.29M | Buy |
+1,171,627
| New | +$3.29M | 0.31% | 33 |
|